
BLTE Stock Forecast & Price Target
BLTE Analyst Ratings
Bulls say
Belite Bio is poised to successfully launch their lead candidate in Stargardt disease (STGD1) - the first ever treatment for this rare, debilitating condition. With a target action date of February 2027, a successful launch would address a significant unmet medical need for ~53k US STGD1 patients and potentially generate ~$5B in peak US sales, while the recent submission of a New Drug Application in Japan provides additional upside potential. Additionally, Belite's strong financial position, with cash and investments totaling $780.0M, mitigates risks related to financing and cash burn.
Bears say
Belite Bio is a clinical-stage biopharmaceutical company with a negative outlook due to various risks including financing risk, clinical risk, and the possibility of facing challenges in gaining market share in a competitive market for its lead drug, tinlarebant, which is being developed for the treatment of degenerative retinal diseases such as GA and STGD1. Despite strong price performance, there are uncertainties surrounding the launch execution and market access efforts for this drug. Additionally, the company's success is dependent on its ability to secure sufficient funding and the safety and efficacy of its products in clinical trials.
This aggregate rating is based on analysts' research of Belite Bio Inc and is not a guaranteed prediction by Public.com or investment advice.
BLTE Analyst Forecast & Price Prediction
Start investing in BLTE
Order type
Buy in
Order amount
Est. shares
0 shares